| Nota di contenuto |
Intro -- Preface -- Contents -- Chapter 1: Polypharmacy in Cancer Therapy -- 1.1 Polypharmacy: Challenges in the Treatment of Chronic Diseases -- 1.2 Scenario of Polypharmacy in Cancer Treatment -- 1.3 Drug Interactions -- 1.3.1 Pharmacodynamic Interactions -- 1.3.2 Pharmacokinetic Interactions -- 1.4 Advantages in Drug Association -- 1.5 Risks of Polypharmacy -- References -- Chapter 2: Combined Therapy for the Treatment of Cancer -- 2.1 Anticancer Therapy -- 2.2 Combination Therapy in Cancer -- 2.2.1 Challenges in Combination Therapy -- 2.3 Toxicity of Combination Therapy for Cancer Treatment -- 2.3.1 Toxicity in the Treatment of Breast Cancer -- 2.3.2 Toxicity in the Treatment of Lung Cancer -- 2.3.3 Toxicity in the Treatment of Colorectal Cancer -- 2.3.4 Toxicity in the Treatment of Prostate Cancer -- 2.3.5 Toxicity in the Treatment of Cervical Cancer -- 2.3.6 Toxicity in the Treatment of Head and Neck Cancer -- 2.3.7 Toxicity in the Treatment of Lymphomas -- References -- Chapter 3: Importance of the Infusion Order in the Treatment of Cancer -- 3.1 Drug Infusion Therapy -- 3.1.1 Types of Infusion According to Administration Time -- 3.2 Dilution of Drugs and Their Stability -- 3.3 Risks of Chemotherapy Infusion -- 3.3.1 Drug Extravasation -- 3.3.1.1 Irritating Antineoplastics -- 3.3.1.2 Vesicant Antineoplastics -- 3.4 Concept and Importance of Infusion Order -- 3.4.1 Factors That May Influence in the Order of Infusion of Antineoplastic Agents -- References -- Chapter 4: Chemotherapeutic Protocols for the Treatment of Breast Cancer -- 4.1 Breast Cancer: Epidemiology -- 4.2 Pathophysiology of Breast Cancer -- 4.3 Molecular Subtypes of Breast Cancer -- 4.4 Breast Cancer Treatment Modalities -- 4.5 Adjuvant Chemotherapy -- 4.5.1 AC Protocol (Doxorubicin and Cyclophosphamide).
4.5.2 ACT, T-AC, or AC-T Protocol (Doxorubicin, Cyclophosphamide, and Paclitaxel) -- 4.5.3 ACTT Protocol (Doxorubicin, Cyclophosphamide, Paclitaxel, and Trastuzumab) -- 4.5.4 CMF Protocol (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) -- 4.5.5 FAC Protocol (5-Fluorouracil, Doxorubicin, and Cyclophosphamide) -- 4.5.6 FEC Protocol (5-Fluorouracil, Epirubicin, and Cyclophosphamide) -- 4.5.7 FEC-D Protocol (5-Fluorouracil, Epirubicin, Cyclophosphamide, and Docetaxel) -- 4.5.8 FEC-DT Protocol (5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) -- 4.5.9 DAC (Docetaxel, Doxorubicin, and Cyclophosphamide) and DC (Docetaxel and Cyclophosphamide) Protocols -- 4.5.10 TDC Protocol (Trastuzumab, Docetaxel, and Cyclophosphamide) -- 4.5.11 DCARBT Protocol (Docetaxel, Carboplatin, and Trastuzumab) -- 4.6 Chemotherapy in Locally Advanced Breast Cancer -- 4.6.1 AC-DT Protocol (Doxorubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) -- 4.6.2 CT-AC Protocol (Carboplatin, Paclitaxel, Doxorubicin, and Cyclophosphamide) -- 4.7 Chemotherapy in Advanced Breast Cancer -- 4.7.1 GEMD Protocol (Gemcitabine and Docetaxel) -- 4.7.2 GEMP Protocol (Gemcitabine and Cisplatin) -- 4.7.3 GEMT Protocol (Gemcitabine and Paclitaxel) -- 4.7.4 PTRAD Protocol (Pertuzumab, Trastuzumab, and Docetaxel) -- 4.7.5 PTRAT Protocol (Pertuzumab, Trastuzumab, and Paclitaxel) -- 4.7.6 TRVIN Protocol (Trastuzumab and Vinorelbine) -- References -- Chapter 5: Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer -- 5.1 Epidemiological Profile of Cancers of the Gastrointestinal Tract -- 5.2 Pathophysiology of Colorectal Cancer -- 5.2.1 Adjuvant Chemotherapy for the Treatment of Resectable Colorectal Cancer -- 5.2.1.1 CAPOX Protocol (Oxaliplatin and Capecitabine) -- 5.2.1.2 FL Protocol (5-Fluorouracil and Leucovorin).
5.2.1.3 FOLFOX Protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil, and 5-Fluorouracil in Continuous Infusion) -- 5.2.1.4 RALOX Protocol (Oxaliplatin and Raltitrexed) -- 5.2.2 Chemotherapy for the Treatment of Advanced Unresectable Colorectal Cancer -- 5.2.2.1 CAPB Protocol (Capecitabine and Bevacizumab) -- 5.2.2.2 CETIR Protocol (Cetuximab and Irinotecan) -- 5.2.2.3 FOLFIRI Protocol (Irinotecan, Leucovorin, 5-Fluorouracil, and 5-Fluorouracil in Continuous Infusion) -- 5.2.2.4 CAPIRI Protocol (Capecitabine and Irinotecan) -- 5.2.2.5 CAPIRIB Protocol (Capecitabine, Irinotecan, and Bevacizumab) -- 5.2.2.6 CAPOXB Protocol (Oxaliplatin, Bevacizumab, and Capecitabine) -- 5.2.2.7 FOLFIRIB Protocol (5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, Irinotecan, and Bevacizumab) -- 5.2.2.8 FOLFIRIPAN Protocol (5-Fluorouracil, Leucovorin, Irinotecan, and Panitumumab) -- 5.2.2.9 FOLFOXB Protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, and Bevacizumab) -- 5.2.2.10 FOLFOXPAN Protocol (Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, and Panitumumab) -- 5.3 Pathophysiology of Esophageal and Stomach Cancers -- 5.3.1 Chemotherapy for the Treatment of Esophageal and Stomach Cancer -- 5.3.1.1 FOLFOXT Protocol (Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, and Trastuzumab) -- 5.3.1.2 FLOT Protocol (Oxaliplatin, 5-Fluorouracil, Leucovorin, and Docetaxel) -- 5.3.1.3 CTRT Protocol (Carboplatin, Paclitaxel, and Radiotherapy) -- 5.3.1.4 FUC Protocol (5-Fluorouracil and Cisplatin) -- 5.3.1.5 CCAPRT Protocol (Cisplatin, Capecitabine, and Radiotherapy) -- 5.3.1.6 CCAPT Protocol (Cisplatin, Capecitabine, and Trastuzumab) -- 5.3.1.7 CFUT Protocol (Cisplatin, 5-Fluorouracil, and Trastuzumab).
5.3.1.8 CAPOXT Protocol (Capecitabine, Oxaliplatin, and Trastuzumab) -- 5.3.1.9 RAMP Protocol (Paclitaxel and Ramucirumab) -- 5.3.1.10 ECCAP Protocol (Epirubicin, Cisplatin, and Capecitabine) -- 5.4 Pathophysiology of Pancreatic, Biliary Tract, and Gallbladder Cancers -- 5.4.1 Chemotherapy for the Treatment of Pancreatic, Biliary Tract, and Gallbladder Cancers -- 5.4.1.1 GEMCIS Protocol (Gemcitabine and Cisplatin) -- 5.4.1.2 FOLFIRINOX Protocol (Irinotecan, Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, and Leucovorin) -- 5.4.1.3 GEMCAP Protocol (Capecitabine and Gemcitabine) -- 5.4.1.4 GEMABR Protocol (Gemcitabine and Nab-Paclitaxel) -- 5.5 Pathophysiology of Liver Cancer -- 5.5.1 Chemotherapy for the Treatment of Liver Cancer -- 5.5.1.1 Nivolumab and Ipilimumab Protocol -- 5.5.1.2 Atezolizumab and Bevacizumab Protocol -- 5.6 Pathophysiology of Carcinoid and Neuroendocrine Tumors -- 5.6.1 Chemotherapy for the Treatment of Carcinoid and Neuroendocrine Tumors -- 5.6.1.1 ETCIS Protocol (Etoposide and Cisplatin) -- 5.6.1.2 DS Protocol (Doxorubicin and Streptozotocin) -- 5.7 Pathophysiology of Anal Cancer -- 5.7.1 Chemotherapy in the Treatment of Anal Cancer -- 5.7.1.1 FUMRT Protocol (5-Fluorouracil, Mitomycin C, and Radiotherapy) -- 5.7.1.2 CAPMRT Protocol (Capecitabine, Mitomycin C, and Radiotherapy) -- References -- Chapter 6: Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer -- 6.1 Epidemiological Profile of Genitourinary Cancers -- 6.2 Pathophysiology of Bladder Cancer -- 6.2.1 Chemotherapy for the Treatment of Bladder Cancer -- 6.2.1.1 BCGIFN Protocol (BCG and Interferon) -- 6.2.1.2 GEMDOC Protocol (Gemcitabine and Docetaxel) -- 6.2.1.3 MVAC Protocol (Methotrexate, Vinblastine, Doxorubicin, and Cisplatin) -- 6.3 Pathophysiology of Prostate Cancer -- 6.3.1 Chemotherapy for the Treatment of Prostate Cancer.
6.4 Testicular Cancer -- 6.4.1 Chemotherapy for the Treatment of Testicular Cancer -- 6.4.1.1 BEP Protocol (Bleomycin, Etoposide, and Cisplatin) -- 6.4.1.2 VIP Protocol (Etoposide, Cisplatin, Ifosfamide, and Mesna) -- 6.4.1.3 TAXGEM Protocol (Paclitaxel and Gemcitabine) -- 6.4.1.4 TIP Protocol (Paclitaxel, Cisplatin, Ifosfamide, and Mesna) -- 6.4.1.5 VEIP Protocol (Vinblastine, Cisplatin, Ifosfamide, and Mesna) -- 6.5 Pathophysiology of Kidney Cancer -- 6.5.1 Chemotherapy for the Treatment of Kidney Cancer -- 6.5.1.1 PEMAX Protocol (Pembrolizumab and Axitinib) -- 6.5.1.2 Avelumab and Axitinib Protocol -- References -- Chapter 7: Chemotherapeutic Protocols for the Treatment of Gynecological Cancer -- 7.1 Epidemiological Profile of Gynecological Cancers -- 7.2 Pathophysiology of Ovarian Cancer -- 7.2.1 Chemotherapy for the Treatment of Epithelial Ovarian Cancer -- 7.2.1.1 CABR Protocol (Carboplatin and Abraxane) -- 7.2.1.2 CAPBEV Protocol (Carboplatin, Paclitaxel, and Bevacizumab) -- 7.2.1.3 CISP Protocol (Cisplatin and Paclitaxel) -- 7.2.1.4 CISPBEV Protocol (Cisplatin, Paclitaxel, and Bevacizumab) -- 7.2.1.5 CAD Protocol (Carboplatin and Docetaxel) -- 7.2.1.6 CAG Protocol (Carboplatin and Gemcitabine) -- 7.2.1.7 PLDC Protocol (Pegylated Liposomal Doxorubicin and Carboplatin) -- 7.2.1.8 BEVG Protocol (Bevacizumab and Gemcitabine) -- 7.2.1.9 BEVPLD Protocol (Bevacizumab and Pegylated Liposomal Doxorubicin) -- 7.2.1.10 BEVP Protocol (Bevacizumab and Paclitaxel) -- 7.2.2 Chemotherapy for the Treatment of Non-epithelial Ovarian Cancer -- 7.3 Pathophysiology of Cervical Cancer -- 7.3.1 Chemotherapy for the Treatment of Cervical Cancer -- 7.4 Pathophysiology of Endometrial Cancer -- 7.4.1 Chemotherapy for the Treatment of Endometrial Cancer -- 7.5 Pathophysiology of Gestational Trophoblastic Neoplasia.
7.5.1 Chemotherapy for the Treatment of Gestational Trophoblastic Neoplasia.
|
Info
Cancer data for good : a history of the Victorian Cancer Registry / / Thomas Kehoe
